Table 1 The expression of ToPo II,MRP, and GST-π and their relationship with clinicopathological factors

Sex

  Male

77

54(70.1%)

29(37.7%)

46(59.7%)

  Female

42

34(81.0%)

1.65

0.198

22(52.4%)

2.40

0.121

15(35.7%)

6.27

0.012*

Age

  ≤50 y

33

24(72.7%)

16(48.5%)

14(42.4%)

  >50 y

86

64(74.4%)

0.03

0.851

35(40.7%)

0.59

0.442

47(54.7%)

1.42

0.232

Tumor size

  ≥5 cm

76

59(77.6%)

35(46.1%)

40(52.6%)

  <5 cm

43

29(67.4%)

1.48

0.224

16(37.2%)

0.88

0.349

21(48.8%)

0.16

0.691

Differentiation

  Well

51

44(86.3%)

20(39.2%)

33(40.5%)

  Moderately

31

20(64.5%)

13(41.9%)

13(41.9%)

  Poorly

37

24(64.9%)

7.04

0.029*

18(48.6%)

0.79

0.672

15(64.7%)

6.47

0.039*

TNM staging

  I/II

39

25(64.1%)

17 (43.6%)

16(41.0%)

  III/IV

80

63(78.8%)

2.92

0.087

34(42.5%)

2.57

0.109

45(56.3%)

2.43

0.119

Lymph node

  Positive

93

71(76.3%)

40(43.0%)

47(50.5%)

  Negative

26

17(65.4%)

1.27

0.260

11(42.3%)

0.004

0.949

14(53.8%)

0.09

0.765